Shandra Eisenga Human Cell and Tissue Product Safety Act
HB1082, the Shandra Eisenga Human Cell and Tissue Product Safety Act, directs the Secretary of Health and Human Services to launch a national, evidence-based education campaign about the risks and benefits of human cell and tissue product transplants. The bill also requires the development and dissemination of educational materials for health care professionals and other relevant stakeholders on organ, tissue, and eye donation, donor screening tests, and related donation practices.
In addition to the public awareness component, the bill strengthens oversight of human cell and tissue products regulated under section 361 of the Public Health Service Act. It creates new civil penalties for violations of FDA regulations governing these products, including per-violation fines, daily penalties for continuing violations, and recovery tied to the retail value of the products involved. The bill also requires FDA to publish information about the Tissue Reference Group, inspection activity, inquiries, and response times, and to provide stakeholder education and workshops to improve regulatory predictability.
The legislation further amends existing law to update FDA’s human cell and tissue product policy work, including a public docket for comments on modernizing regulation and a report to Congress by September 30, 2026. That report must summarize workshop and docket input and make recommendations on issues such as minimal manipulation, homologous use, regulatory burden, scientific developments, access to products, and public health protection.
Overall sentiment appears supportive and reform-oriented, with the bill passing the House of Representatives on June 23, 2025. The available record does not include committee debate or recorded votes, so there is no detailed public transcript of objections or endorsements. The bill’s structure suggests a consensus around improving patient and provider awareness while also clarifying and tightening FDA oversight.
The main points of contention likely center on the balance between public health protection and regulatory burden. Stakeholders in the tissue and regenerative medicine sectors may be concerned about increased enforcement, reporting requirements, and potential impacts on access or innovation, while public health advocates are likely to favor stronger safety standards and clearer FDA guidance. The bill explicitly asks FDA to consider access, scientific developments, and burden in its recommendations, indicating those tradeoffs are central to the measure.
HB1082 would amend the Public Health Service Act to authorize civil penalties for violations of FDA human cell and tissue product requirements and would require new FDA transparency, education, and reporting activities. It would also direct HHS/FDA to collect and publish data on registrations, inspections, inquiries, and response times, and to develop recommendations for modernizing regulation of human cell and tissue products, potentially affecting tissue establishments, manufacturers, clinicians, researchers, and patients.
The bill appears to have a generally favorable, pro-safety and pro-transparency sentiment, as reflected by its passage in the House. Because there are no committee transcripts or recorded floor debates in the provided material, the public record here does not show detailed partisan or stakeholder opposition, but the bill’s emphasis on education, oversight, and modernization suggests it was framed as a public health and regulatory improvement measure.
The likely areas of contention are the new civil penalties, the expanded FDA reporting and workshop requirements, and the broader effort to modernize regulation of human cell and tissue products. Industry and research stakeholders may view these provisions as increasing compliance costs or regulatory uncertainty, while supporters are likely to argue they are necessary to improve safety, transparency, and informed decision-making. The bill itself acknowledges this tension by directing FDA to weigh regulatory burden, access, scientific developments, and public health in its recommendations.